258 related articles for article (PubMed ID: 29193019)
21. Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity.
Hagner PR; Chiu H; Ortiz M; Apollonio B; Wang M; Couto S; Waldman MF; Flynt E; Ramsay AG; Trotter M; Gandhi AK; Chopra R; Thakurta A
Br J Haematol; 2017 Nov; 179(3):399-409. PubMed ID: 28771673
[TBL] [Abstract][Full Text] [Related]
22. Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas.
Chong EA; Ahmadi T; Aqui NA; Svoboda J; Nasta SD; Mato AR; Walsh KM; Schuster SJ
Clin Cancer Res; 2015 Apr; 21(8):1835-42. PubMed ID: 25632047
[TBL] [Abstract][Full Text] [Related]
23. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma.
Witzig TE; Wiernik PH; Moore T; Reeder C; Cole C; Justice G; Kaplan H; Voralia M; Pietronigro D; Takeshita K; Ervin-Haynes A; Zeldis JB; Vose JM
J Clin Oncol; 2009 Nov; 27(32):5404-9. PubMed ID: 19805688
[TBL] [Abstract][Full Text] [Related]
24. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Wiernik PH; Lossos IS; Tuscano JM; Justice G; Vose JM; Cole CE; Lam W; McBride K; Wride K; Pietronigro D; Takeshita K; Ervin-Haynes A; Zeldis JB; Habermann TM
J Clin Oncol; 2008 Oct; 26(30):4952-7. PubMed ID: 18606983
[TBL] [Abstract][Full Text] [Related]
25. Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501).
Morrison VA; Jung SH; Johnson J; LaCasce A; Blum KA; Bartlett NL; Pitcher BN; Cheson BD
Leuk Lymphoma; 2015 Apr; 56(4):958-64. PubMed ID: 24996441
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma.
Maruyama D; Nagai H; Fukuhara N; Kitano T; Ishikawa T; Shibayama H; Choi I; Hatake K; Uchida T; Nishikori M; Kinoshita T; Matsuno Y; Nishikawa T; Takahara S; Tobinai K
Cancer Sci; 2016 Dec; 107(12):1785-1790. PubMed ID: 27616553
[TBL] [Abstract][Full Text] [Related]
27. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
Dreyling M; Jurczak W; Jerkeman M; Silva RS; Rusconi C; Trneny M; Offner F; Caballero D; Joao C; Witzens-Harig M; Hess G; Bence-Bruckler I; Cho SG; Bothos J; Goldberg JD; Enny C; Traina S; Balasubramanian S; Bandyopadhyay N; Sun S; Vermeulen J; Rizo A; Rule S
Lancet; 2016 Feb; 387(10020):770-8. PubMed ID: 26673811
[TBL] [Abstract][Full Text] [Related]
28. Temsirolimus in mantle cell lymphoma and other non-Hodgkin lymphoma subtypes.
Hess G; Smith SM; Berkenblit A; Coiffier B
Semin Oncol; 2009 Dec; 36 Suppl 3():S37-45. PubMed ID: 19963099
[TBL] [Abstract][Full Text] [Related]
29. Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
Ohmachi K; Ando K; Ogura M; Uchida T; Itoh K; Kubota N; Ishizawa K; Yamamoto J; Watanabe T; Uike N; Choi I; Terui Y; Usuki K; Nagai H; Uoshima N; Tobinai K;
Cancer Sci; 2010 Sep; 101(9):2059-64. PubMed ID: 20626754
[TBL] [Abstract][Full Text] [Related]
30. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype.
Hernandez-Ilizaliturri FJ; Deeb G; Zinzani PL; Pileri SA; Malik F; Macon WR; Goy A; Witzig TE; Czuczman MS
Cancer; 2011 Nov; 117(22):5058-66. PubMed ID: 21495023
[TBL] [Abstract][Full Text] [Related]
31. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes.
Cheah CY; Chihara D; Romaguera JE; Fowler NH; Seymour JF; Hagemeister FB; Champlin RE; Wang ML
Ann Oncol; 2015 Jun; 26(6):1175-1179. PubMed ID: 25712454
[TBL] [Abstract][Full Text] [Related]
32. Synergistic Cytotoxicity of Lenalidomide and Dexamethasone in Mantle Cell Lymphoma via Cereblon-dependent Targeting of the IL-6/STAT3/PI3K Axis.
Ma J; Wu K; Bai W; Cui X; Chen Y; Xie Y; Xie Y
EBioMedicine; 2017 Jun; 20():70-78. PubMed ID: 28529032
[TBL] [Abstract][Full Text] [Related]
33. Clinical efficacy and safety in relapsed/refractory mantle cell lymphoma: a systematic literature review.
Njue A; Colosia A; Trask PC; Olivares R; Khan S; Abbe A; Police R; Wang J; Ruiz-Soto R; Kaye JA; Awan F
Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):1-12.e7. PubMed ID: 25052050
[TBL] [Abstract][Full Text] [Related]
34. Clinical outcomes of a novel combination of lenalidomide and rituximab followed by stem cell transplantation for relapsed/refractory aggressive B-cell non-hodgkin lymphoma.
Cai Q; Chen Y; Zou D; Zhang L; Badillo M; Zhou S; Lopez E; Jiang W; Huang H; Lin T; Romaguera J; Wang M
Oncotarget; 2014 Sep; 5(17):7368-80. PubMed ID: 25228589
[TBL] [Abstract][Full Text] [Related]
35. Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma.
Albertsson-Lindblad A; Kolstad A; Laurell A; Räty R; Grønbæk K; Sundberg J; Pedersen LB; Ralfkiær E; Karjalainen-Lindsberg ML; Sundström C; Ehinger M; Geisler C; Jerkeman M
Blood; 2016 Oct; 128(14):1814-1820. PubMed ID: 27354719
[TBL] [Abstract][Full Text] [Related]
36. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation.
Visco C; Finotto S; Zambello R; Paolini R; Menin A; Zanotti R; Zaja F; Semenzato G; Pizzolo G; D'Amore ES; Rodeghiero F
J Clin Oncol; 2013 Apr; 31(11):1442-9. PubMed ID: 23401442
[TBL] [Abstract][Full Text] [Related]
37. Lenalidomide in relapsed refractory non-Hodgkin's lymphoma: An Indian perspective.
Lakshmaiah KC; Rachan Shetty KS; Sathyanarayanan V; Lokanatha D; Abraham LJ; Babu KG
J Cancer Res Ther; 2015; 11(4):857-61. PubMed ID: 26881531
[TBL] [Abstract][Full Text] [Related]
38. Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma.
Ruan J; Martin P; Shah B; Schuster SJ; Smith SM; Furman RR; Christos P; Rodriguez A; Svoboda J; Lewis J; Katz O; Coleman M; Leonard JP
N Engl J Med; 2015 Nov; 373(19):1835-44. PubMed ID: 26535512
[TBL] [Abstract][Full Text] [Related]
39. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma.
Dimopoulos MA; Chen C; Spencer A; Niesvizky R; Attal M; Stadtmauer EA; Petrucci MT; Yu Z; Olesnyckyj M; Zeldis JB; Knight RD; Weber DM
Leukemia; 2009 Nov; 23(11):2147-52. PubMed ID: 19626046
[TBL] [Abstract][Full Text] [Related]
40. Phase II trial and prediction of response of single agent tipifarnib in patients with relapsed/refractory mantle cell lymphoma: a Groupe d'Etude des Lymphomes de l'Adulte trial.
Rolland D; Ribrag V; Haioun C; Ghesquieres H; Jardin F; Bouabdallah R; Franchi P; Briere J; De Kerviler E; Chassagne-Clement C; Raponi M; Houlgatte R; Jais JP; Thieblemont C
Cancer Chemother Pharmacol; 2010 Mar; 65(4):781-90. PubMed ID: 19960345
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]